EA200901536A1 - Пиразолопиримидиноновый ингибитор киназ - Google Patents
Пиразолопиримидиноновый ингибитор киназInfo
- Publication number
- EA200901536A1 EA200901536A1 EA200901536A EA200901536A EA200901536A1 EA 200901536 A1 EA200901536 A1 EA 200901536A1 EA 200901536 A EA200901536 A EA 200901536A EA 200901536 A EA200901536 A EA 200901536A EA 200901536 A1 EA200901536 A1 EA 200901536A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- pyrazolopyrhidinone
- pyrimidin
- compound
- pyrazolo
- activity against
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- VEQNGHIVPALKQD-UHFFFAOYSA-N 1-pyridin-4-yl-2h-pyrazolo[3,4-d]pyrimidin-4-one Chemical class N1C=C2C(=O)N=CN=C2N1C1=CC=NC=C1 VEQNGHIVPALKQD-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- IUYQIJQHYDZUDF-UHFFFAOYSA-N pyrazolo[3,4-d]pyrimidin-4-one Chemical compound O=C1N=CN=C2N=NC=C12 IUYQIJQHYDZUDF-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 238000013414 tumor xenograft model Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93215507P | 2007-05-29 | 2007-05-29 | |
| EP07113226A EP2019101A1 (en) | 2007-07-26 | 2007-07-26 | Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor |
| PCT/EP2008/056569 WO2008145678A1 (en) | 2007-05-29 | 2008-05-28 | Pyrazolopyrimidinone kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200901536A1 true EA200901536A1 (ru) | 2010-06-30 |
Family
ID=38556321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200901536A EA200901536A1 (ru) | 2007-05-29 | 2008-05-28 | Пиразолопиримидиноновый ингибитор киназ |
Country Status (19)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010125004A1 (en) * | 2009-04-29 | 2010-11-04 | Nerviano Medical Sciences S.R.L. | Cdk inhibitor salts |
| US9498471B2 (en) | 2011-10-20 | 2016-11-22 | The Regents Of The University Of California | Use of CDK9 inhibitors to reduce cartilage degradation |
| WO2015172713A1 (zh) * | 2014-05-13 | 2015-11-19 | 广东东阳光药业有限公司 | 一种中间体的制备方法 |
| JP6930913B2 (ja) | 2014-10-14 | 2021-09-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 炎症を阻害するためのｃｄｋ９及びｂｒｄ４阻害剤の使用法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US3916889A (en) * | 1973-09-28 | 1975-11-04 | Sandoz Ag | Patient ventilator apparatus |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4710384A (en) | 1986-07-28 | 1987-12-01 | Avner Rotman | Sustained release tablets made from microcapsules |
| EG18377A (en) | 1986-09-19 | 1993-04-30 | Lilly Co Eli | Process for preparing glycopeptide antibiotics |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6559152B2 (en) * | 1998-10-13 | 2003-05-06 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| US6531477B1 (en) * | 1998-10-13 | 2003-03-11 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| EP1156060B1 (en) | 2000-05-12 | 2007-06-27 | GPC Biotech AG | Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells |
| IT1317975B1 (it) | 2000-06-16 | 2003-07-21 | Christian Pio Pedulla | Presa multipla volante. |
| WO2003033499A2 (en) * | 2001-10-15 | 2003-04-24 | Gpc Biotech Inc. | Inhibitors of cyclin-dependent kinases, compositions and uses related thereto |
| US20040248905A1 (en) * | 2001-07-10 | 2004-12-09 | Markwalder Jay A | 6-Substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| SG173222A1 (en) * | 2003-04-07 | 2011-08-29 | Agennix Usa Inc | Aminoindeno[1,2-c]pyrazol-4-ones as inhibitors of cyclin-dependent kinases, useful for the treatment of alopecia, viral infections and hyperproliferative disorders, a pharmaceutical composition and uses related thereto |
| US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| MXPA06007399A (es) | 2003-12-23 | 2007-01-26 | Gpc Biotech Inc | Inhibidores de quinasas dependientes de ciclina, composiciones y usos relacionados con ellos. |
-
2007
- 2007-07-26 EP EP07113226A patent/EP2019101A1/en not_active Withdrawn
-
2008
- 2008-05-28 HR HR20110768T patent/HRP20110768T1/hr unknown
- 2008-05-28 JP JP2010509817A patent/JP2010528088A/ja active Pending
- 2008-05-28 ES ES08760162T patent/ES2370677T3/es active Active
- 2008-05-28 KR KR1020097027211A patent/KR20100040806A/ko not_active Withdrawn
- 2008-05-28 WO PCT/EP2008/056569 patent/WO2008145678A1/en not_active Ceased
- 2008-05-28 CA CA002689090A patent/CA2689090A1/en not_active Abandoned
- 2008-05-28 AU AU2008257534A patent/AU2008257534A1/en not_active Abandoned
- 2008-05-28 US US12/602,021 patent/US8304418B2/en not_active Expired - Fee Related
- 2008-05-28 AT AT08760162T patent/ATE522533T1/de active
- 2008-05-28 CN CN200880100285A patent/CN101765600A/zh active Pending
- 2008-05-28 EP EP08760162A patent/EP2170891B1/en not_active Not-in-force
- 2008-05-28 MX MX2009012832A patent/MX2009012832A/es not_active Application Discontinuation
- 2008-05-28 EA EA200901536A patent/EA200901536A1/ru unknown
- 2008-05-28 SI SI200830428T patent/SI2170891T1/sl unknown
- 2008-05-28 DK DK08760162.1T patent/DK2170891T3/da active
- 2008-05-28 AR ARP080102229A patent/AR066737A1/es unknown
- 2008-05-29 TW TW097119933A patent/TW200906831A/zh unknown
-
2009
- 2009-11-26 IL IL202375A patent/IL202375A0/en unknown
- 2009-12-15 ZA ZA200908943A patent/ZA200908943B/xx unknown
-
2012
- 2012-10-09 US US13/647,572 patent/US20130035349A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101765600A (zh) | 2010-06-30 |
| WO2008145678A1 (en) | 2008-12-04 |
| AU2008257534A1 (en) | 2008-12-04 |
| AR066737A1 (es) | 2009-09-09 |
| KR20100040806A (ko) | 2010-04-21 |
| SI2170891T1 (sl) | 2011-12-30 |
| IL202375A0 (en) | 2010-06-30 |
| JP2010528088A (ja) | 2010-08-19 |
| ES2370677T3 (es) | 2011-12-21 |
| TW200906831A (en) | 2009-02-16 |
| ATE522533T1 (de) | 2011-09-15 |
| MX2009012832A (es) | 2010-05-17 |
| US8304418B2 (en) | 2012-11-06 |
| EP2019101A1 (en) | 2009-01-28 |
| US20130035349A1 (en) | 2013-02-07 |
| ZA200908943B (en) | 2010-08-25 |
| EP2170891B1 (en) | 2011-08-31 |
| CA2689090A1 (en) | 2008-12-04 |
| US20100160350A1 (en) | 2010-06-24 |
| EP2170891A1 (en) | 2010-04-07 |
| DK2170891T3 (da) | 2011-12-12 |
| HRP20110768T1 (hr) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX342814B (es) | Sales de inhibidor de janus cinasa (r)-3-(4-7h-pirrolo[2,3-d]pirim idin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo. | |
| GEP20115283B (en) | Pyrrolopyrimidine compounds and their uses | |
| EP1945222A4 (en) | PYRROLO [2,1-F] [1,2,4] TRIAZIN-4-YLAMINE DERIVATIVES INHIBITORS OF IGF-1R KINASE FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | |
| TW200745123A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
| WO2006069080A3 (en) | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors | |
| NO20070514L (no) | Pyrrolotriazin kinase inhibitorer | |
| TW200801008A (en) | Protein kinase inhibitors | |
| TW200745128A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
| EA201200132A1 (ru) | ГЕТЕРОАРИЛ-ЗАМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| MX2010005950A (es) | 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa. | |
| ATE420883T1 (de) | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren | |
| ATE378321T1 (de) | Pyrazolopyrimidine | |
| NZ594385A (en) | Aminopyrimidines useful as kinase inhibitors | |
| WO2006124354A3 (en) | Tyrosine kinase inhibitors | |
| IL191832A (en) | Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors | |
| CL2011002956A1 (es) | Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos. | |
| TW200745127A (en) | Pyrazolopyrimidines as protein kinase inhibitors | |
| EP1957078A4 (en) | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER BY INHIBITING AURORA KINASE | |
| ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
| EA200901536A1 (ru) | Пиразолопиримидиноновый ингибитор киназ | |
| EA200870454A1 (ru) | Способ ингибирования c-kit киназы | |
| WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
| WO2007050380A3 (en) | Tyrosine kinase inhibitors | |
| WO2006078575A3 (en) | Fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido[3,4- d] pyrimidines as inhibitors of mitotic kinesins | |
| EA200800223A1 (ru) | ПРОИЗВОДНЫЕ ПИРИДО[2,3-d]ПИРИМИДИНА, ИХ ПОЛУЧЕНИЕ, ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ |